Abstract
The overall prognosis for patients with perihilar cholangiocarcinoma (PHC) is dismal. Resection of the tumor remains the only curative treatment, but only 10–20% of patients have resectable disease at the time of diagnosis [1]. The majority of patients present with locally advanced disease or lymph node metastases upon presentation or during exploratory laparotomy which makes resection not amenable. As the prognosis of patients with locally advanced PHC (LAPHC) or PHC with lymph node metastases in the palliative setting is significantly better compared to patients with organ metastases [2], ablative therapies may be of use for symptom palliation and potential survival benefit. Unfortunately, current ablative techniques for LAPHC are limited by serious side effects. These limitations may be overcome by irreversible electroporation (IRE), of which the safety and feasibility have been demonstrated in the presence of main bile ducts and large vascular structures [3–5].
References
Khan SA, et al. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.
Ruys AT, et al. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World J Surg. 2012;36(9):2179–86.
Scheffer HJ, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25(7):997–1011. quiz 1011.
Kingham TP, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215(3):379–87.
Silk MT, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–8.
Popescu I, et al. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg. 2014;399(6):693–705.
Matsuo K, et al. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012;215(3):343–55.
Gores GJ, et al. Liver transplantation for perihilar cholangiocarcinoma. Dig Dis. 2013;31(1):126–9.
Darwish MS, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012;56(3):972–81.
Valle J, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
Cheon YK, et al. Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB (Oxford). 2012;14(3):185–93.
Goldberg SN, et al. Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol. 1998;9(1):101–11.
Silk MT, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Interv Radiol. 2014;25(1):112–8.
Kingham TP, et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg. 2012;215(3):379–87.
José A, et al. Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett. 2012;317(1):16–23.
Garon EB, et al. In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. Int J Cancer. 2007;121(3):675–82.
Bower M, et al. Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011;104(1):22–8.
Charpentier KP, et al. Irreversible electroporation of the pancreas in swine: a pilot study. HPB (Oxford). 2010;12(5):348–51.
Narayanan G, et al. Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol. 2014;37(6):1523–9.
Melenhorst MC, et al. Percutaneous irreversible electroporation of unresectable hilar cholangiocarcinoma (Klatskin tumor): a case report. Cardiovasc Intervent Radiol. 2016;39(1):117–21.
Coelen RJ, et al. Diagnostic accuracy of staging laparoscopy for detecting metastasized or locally advanced perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surg Endosc. 2016;30(10):4163–73.
Scheffer HJ, et al. The Influence of a metal stent on the distribution of thermal energy during irreversible electroporation. PLoS One. 2016;11(2):e0148457.
Lu DS, et al. Irreversible electroporation: ready for prime time? Tech Vasc Interv Radiol. 2013;16(4):277–86.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Roos, E., Vroomen, L.G.P.H., van Veldhuisen, E., Coelen, RJ., van Gulik, T.M., Meijerink, M.R. (2018). Irreversible Electroporation for Perihilar Cholangiocarcinoma (Klatskin Tumors). In: Meijerink, M., Scheffer, H., Narayanan, G. (eds) Irreversible Electroporation in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-55113-5_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-55113-5_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55112-8
Online ISBN: 978-3-319-55113-5
eBook Packages: MedicineMedicine (R0)